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Introduction: Aldosterone mediates sodium and water retention 
in hypovolemia. In normovolemia, aldosterone primarily mediates 
kaliuresis. To mediate kaliuresis, aldosterone downregulates the 
sodium chloride cotransporters NCC and up-regulates the epithe-
lial sodium channel ENaC. NCC downregulation increases sodium 
chloride transport to ENaC, where it is reabsorbed in turn for potas-
sium, which is then excreted. We investigated whether kaliuresis is 
associated with the aldosterone receptor polymorphism rs3857080 
in normovolemic healthy volunteers.
Patients (or Materials) and Methods: We genotyped 195 healthy 
young men for rs3858070. In a triple-crossover study, 101 of them 
had ingested a sodium-chloride restricted diet 3 times for each a diet 
run-in day, a second diet day and a third diet plus verum day. Verums 
were 25-mg hydrochlorothiazide (HCT), 100-mg HCT and 200-mg 
triamterene. In a second triple-crossover study, 94 men took single 
oral doses of bumetanide (2 mg), furosemide (80 mg), and torsemide 
(10 mg). To avoid hypovolemia, the subjects were repetitively encour-
aged to drink in both studies.
Results: Potassium excretion was in both studies associated 
with rs3857080, which had a minor allele frequency of 0.111. 
Comparatively high potassium excretion was associated with the 
minor A-allele under most conditions (Table). After torsemide, which 
is a loop diuretic such as bumetanide and furosemide but in addi-
tion blocks the aldosterone receptor, potassium excretion was similar 
between the A- and the G-allele of rs3857080.
Table.  Urinary potassium excretion over 24 hours and  
rs3857080.
A/A G/G
NaCl restriction 3.7 (0.2)* 2.8 (0.1)
HCT 25 mg 4.8 (0.6) 3.7 (0.1)
HCT 100 mg 5.5 (0.6) 4.1 (0.1)
Triamterene 3.3 (0.5) 2.2 (0.1)
Bumetanide 3.5 (0.3) 2.8 (0.1)
Furosemide 3.5 (0.3) 3.1 (0.1)
Torsemide 2.5 (0.3) 2.6 (0.1)
*Mean (SEM) of gram amounts normalized to 120 mL/min creatinine clearance.
Conclusion: Taken together, our findings indicate that the A-allele 
of rs3857080 marks a comparatively active aldosterone recep-
tor. Carriers of the A-allele may be prone to hypokalemia and its 
devastating consequences. The A-allele of rs3857080 may predict 
less optimal outcome of diuretic therapy and of heart diseases. 
Antialdosteronergic drugs such as spironolactone, eplerenone, and 
torsemide may be especially indicated in carriers of the A-allele. In 
consequence, rs3857080 is a highly promising candidate for in vitro 
studies as well as for clinical research.
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Introduction: Despite plentiful sunshine in the Middle East, popu-
lations in general, and in Lebanon in particular, have some of the 
lowest levels of 25-hydroxy vitamin D (25-OHD) worldwide. Our 
group has demonstrated such findings across the lifespan; predic-
tors include gender, season, and clothing style (http://staff.aub.edu.
lb/~webcmop/publications.html). However, the possibility of an 
underlying genetic modulation of circulating 25-OHD levels remains 
unexplored. 25-Hydroxylation is mainly driven by cytochrome P-450 
2R1 (CYP2R1) drug metabolizing enzyme; we therefore hypothesized 
that carriage of CYP2R1 single nucleotide polymorphisms (SNPs) 
may be associated with variability in 25-OHD levels.
Patients (or Materials) and Methods: Baseline 25-OHD levels were 
obtained for 172 elderly Lebanese patients: 60% female; age, 70.9 
(4.3) (mean [SD]) years; BMI, 30.3 (4.8) kg/m2; with vitamin D, 
25-OHD, 18.7 (7.9) ng/mL. Genotyping was performed for 4 func-
tionally important SNPs (rs12794714, rs10741657, rs1562902, and 
rs10766197) in CYP2R1 gene by using real-time PCR. Means were 
first compared with univariate analysis, and then multivariate regres-
sion analysis was run adjusting for age, gender, BMI, and season.
Results: Minor allele frequencies were 0.50, 0.29, 0.36, and 0.49 for 
rs12794714, rs10741657, rs1562902, and rs10766197, respectively; 
proportions comparable to those reported in Caucasian popula-
tions. Univariate analysis showed that carriers of the rs12794714 and 
rs10766197 variant alleles are associated with baseline 25-OHD that was 
3.24 ng/mL and 4.48 ng/mL lower, respectively (P = 0.018 and 0.004). 
This significant association remained for rs10766197 after adjusting for 
covariates (β = –6.401 [95% CI, –11.775 to –1.027]; P = 0.020).
Conclusion: This is the first study that shows the association of 
genetic polymorphisms in CYP2R1 with hypovitaminosis D in the 
Middle East. Further analysis is ongoing to evaluate the effect of 
these SNPs on 25-OHD levels achieved after supplementation with 
different doses of vitamin D.
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